A Vascular Permeability Assay Using an In Vitro Human Microvessel Model Mimicking the Inflammatory Condition

The vascular barrier is an important function of the endothelium and its dysfunction is involved in several diseases. The barrier function of the endothelial cell monolayer is governed by cell-cell, cell-extracellular matrix (cell-ECM) contacts, and inflammatory factors such as thrombin, histamine or vascular endothelial growth factor. Several in vivo and in vitro assays that measure the vascular permeability induced by these factors have been developed. However, they suffer limitations such as being challenging for assessing details of biological processes at a cellular level or lacking the architecture of a vessel, that raise the need for new methods. In vitro 3D model-based assays have thus been developed but assays for investigating compounds that protects the barrier function are lacking. Here we describe the development of an in vitro three-dimensional (3D) vascular endothelium model in which we can manipulate the endothelial barrier function and permeability to molecules, which have a molecular weight similar to human serum albumin, allowing to assess the protective effect of compounds. A microvessel was prepared by culturing human umbilical vein endothelial cells (HUVECs) within a collagen gel on a polydimethylsiloxane (PDMS) chip. Using fluorescein isothiocyanate (FITC)-conjugated dextran (70 kDa, FITC-dextran) and confocal fluorescence microscopy, we showed that the microvessel presented an effective barrier function. We were then able to induce the loss of this barrier function by treatment with the inflammatory factor thrombin. The loss of barrier function was quantified by the extravasation of FITC-dextran into collagen matrix. Furthermore, we were able to analyze the protective effect on the endothelial barrier function of the cyclic adenosine monophosphate (cAMP) analog, 8-pCPT-2'-O-Me-cAMP (also called 007). In an attempt to understand the effects of thrombin and 007 in our model, we analyzed the adherens junctions and cytoskeleton through immunostaining of the vascular endothelial cadherin and actin, respectively. Our assay method could be used to screen for compounds modulating the barrier function of endothelial cells, as well as investigating mechanistic aspects of barrier dysfunction.

[1]  A. Khademhosseini,et al.  Cell-microenvironment interactions and architectures in microvascular systems. , 2016, Biotechnology advances.

[2]  Johan Karlsson,et al.  Review: in vitro microvessel models. , 2015, Lab on a chip.

[3]  Lena Claesson-Welsh,et al.  Vascular permeability—the essentials , 2015, Upsala journal of medical sciences.

[4]  Dolly Mehta,et al.  Mechanisms Regulating Endothelial Permeability , 2014, Pulmonary circulation.

[5]  Ali Khademhosseini,et al.  Microfluidic techniques for development of 3D vascularized tissue. , 2014, Biomaterials.

[6]  J. Gavard Endothelial permeability and VE-cadherin , 2013, Cell adhesion & migration.

[7]  F. Auger,et al.  The pivotal role of vascularization in tissue engineering. , 2013, Annual review of biomedical engineering.

[8]  Brendon M. Baker,et al.  Microfluidics embedded within extracellular matrix to define vascular architectures and pattern diffusive gradients. , 2013, Lab on a chip.

[9]  Hyunjae Lee,et al.  Engineering of functional, perfusable 3D microvascular networks on a chip. , 2013, Lab on a chip.

[10]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[11]  R. Klein,et al.  Diabetic retinopathy. , 2012, The New England journal of medicine.

[12]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[13]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[14]  James G Truslow,et al.  The role of cyclic AMP in normalizing the function of engineered human blood microvessels in microfluidic collagen gels. , 2010, Biomaterials.

[15]  N. Mochizuki,et al.  Vascular Endothelial-Cadherin Stabilizes at Cell–Cell Junctions by Anchoring to Circumferential Actin Bundles through α- and β-Catenins in Cyclic AMP-Epac-Rap1 Signal-activated Endothelial Cells , 2010, Molecular biology of the cell.

[16]  野田 一臣 Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to circumferential actin bundles through α- and β-catenins in cyclic AMP-Epac-Rap1 signal-activated endothelial cells , 2010 .

[17]  Sara M Weis,et al.  Vascular permeability in cardiovascular disease and cancer , 2008, Current opinion in hematology.

[18]  A. Malik,et al.  Regulation of Endothelial Junctional Permeability , 2008, Annals of the New York Academy of Sciences.

[19]  D. Vestweber,et al.  VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[20]  F. Orsenigo,et al.  Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees , 2008, Cell and Tissue Research.

[21]  A. Malik,et al.  Dual Regulation of Endothelial Junctional Permeability , 2007, Science's STKE.

[22]  E. Dejana,et al.  The role of junctional adhesion molecules in vascular inflammation , 2007, Nature Reviews Immunology.

[23]  J. Folkman Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[24]  Joe Tien,et al.  Formation of perfused, functional microvascular tubes in vitro. , 2006, Microvascular research.

[25]  A. Malik,et al.  Signaling mechanisms regulating endothelial permeability. , 2006, Physiological reviews.

[26]  M. Corada,et al.  Epac1 regulates integrity of endothelial cell junctions through VE‐cadherin , 2005, FEBS letters.

[27]  T. Mayadas,et al.  Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. , 2005, Blood.

[28]  S. Døskeland,et al.  A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK , 2002, Nature Cell Biology.

[29]  E. de Juan,et al.  Normalization of retinal vascular permeability in experimental diabetes with genistein. , 2001, Investigative ophthalmology & visual science.

[30]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[31]  M. Lampugnani,et al.  Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[32]  D. Atsma,et al.  cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. , 1995, Circulation research.

[33]  G. Thurston,et al.  Thrombin-induced increase of F-actin in human umbilical vein endothelial cells. , 1994, Microvascular research.

[34]  H. Granger,et al.  Permeability to albumin in isolated coronary venules. , 1993, The American journal of physiology.

[35]  A. Malik,et al.  Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Cooper,et al.  Molecular sieving characteristics of the cultured endothelial monolayer , 1987, Journal of cellular physiology.

[37]  A. A. Miles,et al.  Vascular reactions to histamine, histamine‐liberator and leukotaxine in the skin of guinea‐pigs , 1952, The Journal of physiology.